AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
Suzanne Delaney, AstraZeneca
S
Advertisement
ONE TO WATCH:
Suzanne Delaney, ED, Brand Leader, Breast/Prostate, AstraZeneca
An AZ vet, Delaney directs strategy for four of the drug giant's oncology brands, including Armidex, with over $1.25 billion in global sales last year. She won plaudits from her early days carrying the bag, but once she began managing people, her career really took flight. Her model of leadership is based on authenticity. "I don't think age equates in any way to great leadership," she says.
Articles in this issue
over 18 years ago
Mary Szela, Abbottover 18 years ago
Mightier Than the Swordover 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsover 18 years ago
Eric Floyd, Cephalonover 18 years ago
Nancy Phelan, Wyethover 18 years ago
Tightening the Chainover 18 years ago
Kurt Graves, Vertexover 18 years ago
Wendy Niebler, Shireover 18 years ago
Perfectly ImperfectAdvertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
The Battle to Own the GLP-1 Patient Journey
5